Physician profile
Patrick J Walsh
NPI 1417993130
$3,752.58
in general payments reported to CMS, 2019-2025
38 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $241 · 2021: $138 · 2022: $479 · 2023: $499 · 2024: $605 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $718.46 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $644.16 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $310.92 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $307.19 | 2019-2025 | Lumenis Pulse 120h, Lithovue, Spaceoar Vue System - 10ml |
| Pfizer INC. | $200.94 | 2019-2025 | |
| Janssen Biotech, INC. | $156.16 | 2019-2023 | Erleada |
| Teleflex LLC | $120.07 | 2022-2024 | Urolift |
| Olympus America INC. | $113.23 | 2020-2025 | Itind System, Uropass |
| Endo Pharmaceuticals INC. | $108.46 | 2019-2024 | Aveed, Xiaflex |
| Abbvie INC. | $92.37 | 2022-2025 | Botox |
| Endo USA, INC. | $85.94 | 2025 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $63.00 | 2023-2025 | Prolaris |
| Urovant Sciences INC | $59.08 | 2022 | |
| Abc Home Medical Supply, INC. | $53.75 | 2025 | |
| Blue Earth Diagnostics | $51.61 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $51.20 | 2023-2025 | Eclipse |
| Calyxo, INC. | $50.82 | 2024-2025 | Cvac Aspiration System |
| Myovant Sciences INC. | $47.86 | 2021 | |
| Immunitybio, INC. | $42.90 | 2025 | |
| Progenics Pharmaceuticals, INC. | $42.80 | 2025 | |
| Urogen Pharma, INC. | $41.38 | 2022-2025 | |
| Convatec INC. | $40.03 | 2023 | |
| Coloplast Corp | $37.44 | 2023-2025 | Saffron |
| Hollister Incorporated | $34.17 | 2023 | Vapro, Onli, Infyna Chic |
| Tolmar, INC. | $26.34 | 2023 | |
| Accord Healthcare, INC. | $25.94 | 2022 | |
| 180 Medical, INC. | $25.73 | 2025 | Gentlecath |
| Merck Sharp & Dohme LLC | $23.51 | 2023 | Keytruda, Lynparza |
| Antares Pharma, INC. | $22.93 | 2020 | |
| Smith+Nephew, INC. | $22.58 | 2025 | Stravix |
| Bayer Healthcare Pharmaceuticals INC. | $20.19 | 2019 | |
| Profound Medical Corp. | $19.83 | 2025 | Tulsa-Pro |
| Lilly USA, LLC | $18.66 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $16.60 | 2025 | Arexvy |
| Novo Nordisk INC | $14.96 | 2024 | |
| Axonics, INC. | $14.08 | 2022 | |
| Travere Therapeutics, INC. | $13.84 | 2019 | |
| Photocure INC | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.